Published in Nat Rev Drug Discov on November 01, 2004
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse. Invest New Drugs (2006) 0.81
An array of problems. Nat Rev Drug Discov (2005) 2.55
Drug discovery: playing dirty. Nature (2005) 2.12
Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol (2012) 1.88
2004 approvals: the demise of the blockbuster? Nat Rev Drug Discov (2005) 1.58
Set back to Alzheimer vaccine studies. Nat Med (2002) 1.43
Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol (2011) 1.17
Bortezomib. Nat Rev Drug Discov (2003) 1.09
The trouble with making combination drugs. Nat Rev Drug Discov (2006) 0.99
FDA publishes analysis of the pipeline problem. Nat Rev Drug Discov (2004) 0.93
How to avoid another 'Vioxx'. Nat Rev Drug Discov (2005) 0.91
Kidney specificity of rat chromosome 1 blood pressure quantitative trait locus region. Hypertension (2002) 0.86
Pipeline problems are increasing the urge to merge. Nat Rev Drug Discov (2006) 0.86
2003 approvals: a year of innovation and upward trends. Nat Rev Drug Discov (2004) 0.84
Pharma companies becoming more aggressive towards generics firms. Nat Rev Drug Discov (2006) 0.83
Drug approval triggers debate on future direction for cancer treatments. Nat Rev Drug Discov (2006) 0.83
How academia can help drug discovery. Nat Rev Drug Discov (2004) 0.82
Safety concerns raised over RNA interference. Nat Rev Drug Discov (2006) 0.82
New drug approvals for 2002. Nat Rev Drug Discov (2003) 0.80
Pharma's year of trouble and strife. Nat Rev Drug Discov (2006) 0.80
Pharma faces major challenges after a year of failures and heated battles. Nat Rev Drug Discov (2007) 0.80
Therapeutic area influences drug development costs. Nat Rev Drug Discov (2004) 0.79
Cancer drugs could now discover X factor. Nat Rev Drug Discov (2005) 0.79
Industry sweats after patent verdict. Nat Rev Drug Discov (2006) 0.77
Lessons learnt from Genasense's failure. Nat Rev Drug Discov (2004) 0.77
Chemistry outsourcing going global. Nat Rev Drug Discov (2006) 0.75
Better antibiotics through chemistry. Nat Rev Drug Discov (2004) 0.75
Big companies helped by safe harbour ruling. Nat Rev Drug Discov (2005) 0.75
Scientists slam rationale behind largest HIV vaccine trial. Nat Rev Drug Discov (2004) 0.75
New bill aims to reform US patent system. Nat Rev Drug Discov (2006) 0.75
Iressa failure raises fears about accelerated approvals. Nat Rev Drug Discov (2005) 0.75
New neglected disease research scheme pools IP and expertise. Nat Rev Drug Discov (2012) 0.75
Aventis-Sanofi: a good R&D merger? Nat Rev Drug Discov (2004) 0.75
Antidepressant use in children questioned. Nat Rev Drug Discov (2003) 0.75
Europe fiddles while innovation burns. Nat Rev Drug Discov (2005) 0.75
Calls for full disclosure of clinical trials. Nat Rev Drug Discov (2004) 0.75
Another long leaderless period in store for FDA. Nat Rev Drug Discov (2004) 0.75
Fine print TRIPS up multinational and Indian companies. Nat Rev Drug Discov (2005) 0.75
The biotechnology sector's craving for commercial expertise is fuelling a cultural exchange with drug industry. Nature (2003) 0.75
Vioxx fears prompt call for user fee evaluation. Nat Rev Drug Discov (2005) 0.75
PPPs succeeding in tackling neglected diseases. Nat Rev Drug Discov (2005) 0.75
Caution remains over stem cells despite breakthrough. Nat Rev Drug Discov (2005) 0.75
Study reveals secrets to faster drug development. Nat Rev Drug Discov (2006) 0.75
Groups question existence of metabolic syndrome. Nat Rev Drug Discov (2005) 0.75
Heartbeat clue to diagnosing vCJD. Nat Med (2002) 0.75
Vaccine approach for Alzheimer's disease revisited. Nat Rev Drug Discov (2004) 0.75
Study shows newer schizophrenia treatments no more effective than old. Nat Rev Drug Discov (2005) 0.75
Drug safety special: chasing shadows. Nature (2005) 0.75